FDA Accepts Lenalidomide ANDA217281 Submission from Novugen
The FDA has accepted the Abbreviated New Drug Application (ANDA) for Lenalidomide submitted by Novugen.
Asset / Drug
Drug and asset intelligence for Novugen with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.